Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cyclophosphamide
Find trials that include:  Any drugs shown
Results 1-25 of 300 for your search:
Start Over
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Status: Active
Phase: Phase IV
Type: Treatment
Age: 17 and under
Trial IDs: CDR0000667369, NCI-2014-02026, EU-21011, EUDRACT-2007-004092-19, EURONET-PHL-LP1, NCT01088750
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 72
Trial IDs: CS001P3, NCI-2014-01668, 2010-019952-35, NCT01265849
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756
Double Cord Versus Haploidentical (BMT CTN 1101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGN35-014, NCI-2013-00462, 2012-002751-42, NCT01777152
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Ibrutinib and Rituximab Compared with Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: E1912, NCI-2014-00118, ECOG-E1912, NCT02048813
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 65
Trial IDs: BMTCTN1301, NCI-2015-01813, U01HL069294, NCT02345850
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Not yet active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
Start Over